CDC plans to monitor over 30 pathogens in high-risk airports; a surge in ketamine prescriptions raises questions about safety and oversight; changes to come in Affordable Care Act (ACA) enrollment for 2023.
The CDC is set to enhance its traveler-based surveillance program by adding respiratory virus testing, according to Reuters. The expansion will begin at 4 major US airports, with a focus on the upcoming fall and winter seasons, known for the increased circulation of respiratory diseases like influenza and respiratory syncytial virus (RSV). This proactive approach is driven by the CDC's warning of similar or higher hospitalization rates for COVID-19, RSV infections, and flu compared with the previous year, even exceeding prepandemic levels. The collaboration will closely monitor over 30 pathogens through voluntary nasal swabbing and airport wastewater sampling as part of a public-private partnership.
As opioid painkiller prescriptions decline in the United States, ketamine is emerging as a new option for managing hard-to-treat pain and mental health conditions, according to the Associated Press. The surge in ketamine prescriptions, driven by for-profit clinics and telehealth services, is raising concerns due to limited research on its effectiveness and potential safety and abuse risks. While some patients report positive outcomes, others experience adverse effects, including hallucinations and disturbing thoughts, highlighting the need for further study and oversight of ketamine prescribing, experts say.
The open enrollment period for health insurance plans through the Affordable Care Act (ACA) marketplace is underway, offering new features and potential benefits for prospective customers, according to The Hill. The enrollment period runs until January 15, with an important deadline of December 15 for coverage beginning on January 1. Factors such as increased subsidies, ongoing disenrollment from Medicaid, extended document submission timelines, and an automatic reenrollment policy are expected to influence this year's enrollment numbers. Additionally, stronger insurer participation is increasing the options available to consumers, but it may also present challenges in terms of choice complexity. The ACA Navigator program is available to assist consumers in navigating the more crowded marketplace, with increased investments by the Biden administration to support these efforts.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More